These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6705136)

  • 21. Alteration of rat bone marrow megakaryocytes following administration of cytosine arabinoside, daunomycin and hydroxyurea.
    Jerushalmy Z; Payta M; Pinkhas J; De Vries A
    Haemostasis; 1977; 6(2):110-7. PubMed ID: 863292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative impulsecytophotometric and morphological studies of the bone marrow of the rat after daunomycin (author's transl)].
    Wehbe S; Düllmann J; Linden WA; Reddy SB; Brückner V
    Res Exp Med (Berl); 1974; 162(1):67-74. PubMed ID: 4810841
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical study of daunomycin (NSC-82151) in children with acute leukemia.
    Holton CP; Lonsdale D; Nora AH; Thurman WG; Vietti TJ
    Cancer; 1968 Nov; 22(5):1014-7. PubMed ID: 5686634
    [No Abstract]   [Full Text] [Related]  

  • 24. Daunomycin metabolism in rat tissue slices.
    Bachur NR; Cradock JC
    J Pharmacol Exp Ther; 1970 Nov; 175(2):331-7. PubMed ID: 5481703
    [No Abstract]   [Full Text] [Related]  

  • 25. Therapeutic effect of treatment with polyclonal or monoclonal antibodies to alpha-fetoprotein that have been conjugated to daunomycin via a dextran bridge: studies with an alpha-fetoprotein-producing rat hepatoma tumor model.
    Tsukada Y; Ohkawa K; Hibi N
    Cancer Res; 1987 Aug; 47(16):4293-5. PubMed ID: 2440563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A study of daunomycin rats--is it possible to use daunomycin rats as an experimental model of chronic renal failure?].
    Shimizu K; Shibata M
    Nihon Jinzo Gakkai Shi; 1989 Apr; 31(4):345-51. PubMed ID: 2747007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low toxicity and high antitumour activity of daunomycin by conjugation to an immunopotential amphoteric branched polypeptide.
    Gaál D; Hudecz F
    Eur J Cancer; 1998 Jan; 34(1):155-61. PubMed ID: 9624251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osseous changes and abnormalities of mineral metabolism in daunomycin rats.
    Shimizu K; Maeda K; Shibata M; Ise M; Sugano M; Uehara Y
    Nihon Jinzo Gakkai Shi; 1990 Aug; 32(8):863-9. PubMed ID: 2250403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin.
    Juliano RL; Stamp D
    Biochem Pharmacol; 1978 Jan; 27(1):21-7. PubMed ID: 619903
    [No Abstract]   [Full Text] [Related]  

  • 30. [Preliminary studies on the distribution and excretion of tritiated daunomycin in men].
    Di Fronzo G; Bonadonna G
    Tumori; 1969; 55(5):263-75. PubMed ID: 5381785
    [No Abstract]   [Full Text] [Related]  

  • 31. Antibody-directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody.
    Ríhová B; Kopecková P; Strohalm J; Rossmann P; Vĕtvicka V; Kopecek J
    Clin Immunol Immunopathol; 1988 Jan; 46(1):100-14. PubMed ID: 2891460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in uptake of adriamycin and daunomycin by normal BM cells and acute leukemia cell determined by flow cytometry.
    Sonneveld P; van den Engh GJ
    Leuk Res; 1981; 5(3):251-7. PubMed ID: 7266019
    [No Abstract]   [Full Text] [Related]  

  • 33. Equilibrium, kinetic and photoaffinity labeling studies of daunomycin binding to P-glycoprotein-containing membranes of multidrug-resistant Chinese hamster ovary cells.
    Busche R; Tümmler B; Cano-Gauci DF; Riordan JR
    Eur J Biochem; 1989 Jul; 183(1):189-97. PubMed ID: 2568928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Daunomycin rats. Second Report. Is it possible to use daunomycin rats as an experimental model of chronic renal failure?].
    Shimizu K; Maeda K; Shibata M; Ise M; Sugano M; Uehara Y
    Nihon Jinzo Gakkai Shi; 1990 Feb; 32(2):137-45. PubMed ID: 2352357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat.
    Cusack BJ; Young SP; Vestal RE; Olson RD
    Cancer Chemother Pharmacol; 1997; 39(6):505-12. PubMed ID: 9118462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mode of action of chemotherapy in vivo on human acute leukemia. I. Daunomycin.
    Stryckmans PA; Manaster J; Lachapelle F; Socquet M
    J Clin Invest; 1973 Jan; 52(1):126-33. PubMed ID: 4509140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microbial metabolism of anthracycline antibiotics daunomycin and adriamycin.
    Marshall VP; McGovren JP; Richard FA; Richard RE; Wiley PF
    J Antibiot (Tokyo); 1978 Apr; 31(4):336-42. PubMed ID: 26650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Doxorubicin and daunorubicin plasmatic, hepatic and renal disposition in the rabbit with or without enterohepatic circulation.
    Maniez-Devos DM; Baurain R; Lesne M; Trouet A
    J Pharmacol; 1986; 17(1):1-13. PubMed ID: 3713196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo studies on the distribution of 3H-daunomycin in tumours and in different tissues of the mouse.
    Di Fronzo G; Gambetta R
    Rev Eur Etud Clin Biol; 1971; 16(1):50-5. PubMed ID: 5108176
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 2nd communication: distribution and transfer into the fetus and milk after a single intravenous administration and pharmacokinetics and enzyme induction after repeated intravenous administration to rats.
    Sugimoto T; Hayashi T; Okita A; Morino A
    Arzneimittelforschung; 1996 Feb; 46(2):114-27. PubMed ID: 8720299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.